Intro

This chapter discusses the FDA's recent decision to abolish the clozapine REMS program and its implications for both clinicians and patients. It emphasizes the reduced risks after the first year of treatment and explores new monitoring practices and the importance of patient education.

Transcript

Play full episode

Remember Everything You Learn from Podcasts

Save insights instantly, chat with episodes, and build lasting knowledge - all powered by AI.

Get the app